



Ref: FOIA Reference 2023/24-529

Date: 27<sup>th</sup> November 2023

Email [foi@uhn.nhs.uk](mailto:foi@uhn.nhs.uk)

Dear

I am writing to acknowledge receipt of your email dated 10th September 2023 requesting information under the Freedom of Information Act (2000) regarding cancer

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

**Q1 I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.**

**How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- **CAPOX (Capecitabine with Oxaliplatin)**
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
- **Lonsurf (Trifluridine - tipiracil)**
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

:

- CAPOX (Capecitabine with Oxaliplatin) - 5
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) - 0

- Lonsurf (Trifluridine - tipiracil) - 0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0
- Any other systemic anti-cancer therapy - 7
- Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

**Q2 How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- **Nivolumab monotherapy or combination with Ipilimumab**
- **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5  
*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Nivolumab monotherapy or combination with Ipilimumab - <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) - 0
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - 24
- Any other systemic anti-cancer therapy - 18
- Palliative care only - data not held for patients on Best Supportive Care, as not on active SACT (Systemic Anti-Cancer Therapy)

**Q3 How many patients were treated in the past 3 months for ovarian cancer (any stage) with:**

- **Paclitaxel in combination with a platinum-based compound**
- **Platinum-based therapy alone (cisplatin or carboplatin)**
- **Bevacizumab in combination with paclitaxel and carboplatin**
- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**

- **Rucaparib**

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

- Paclitaxel in combination with a platinum-based compound - 13
- Platinum-based therapy alone (cisplatin or carboplatin) - 7
- Bevacizumab in combination with paclitaxel and carboplatin - <5
- Olaparib - <5
- Olaparib + Bevacizumab - <5
- Niraparib - 13
- Rucaparib – <5
- Any other systemic anti-cancer therapy - 15

**Q4 If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive ovarian cancer patients were treated in the last 3 months with:**

- **Olaparib**
- **Olaparib + Bevacizumab**
- **Niraparib**
- **Other treatments**

A4 Information not held

**Q5 Does your Trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.**

A5 See below:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

Yours,



**Rachel Montinaro**  
Data Security and Protection Manager - Records